Treatment of ALK+ Non–Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918)

PURPOSEALK rearrangements occur in 5.4% of Brazilian patients with non–small cell lung cancer (NSCLC). Data on treatment patterns, access to ALK inhibitors, and survival outcomes are scarce.MATERIALS AND METHODSLACOG/GBOT 1918 is a retrospective, observational study that included patients diagnosed...

Descripció completa

Dades bibliogràfiques

Autors principals:	Eldsamira Mascarenhas, Ana C. Z. Gelatti, Tatiane Montella, Marcelo Corassa, William N. William, Rosely Yamamura, Clarissa Baldotto, Eduardo H. Cronemberger, Aknar F. C. Calabrich, Giuliano S. Borges, Carlos H. A. Teixeira, Danielli Matias, Aline F. Fares, Cristina D. A. T. Sampaio, Antonia Angeli Gazola, Francisco de C. Zuanazzi, Paulo A. C. Schulze, Luísa M. T. Franche, Rafaela G. de Jesus, Juliana Giacomazzi, Matheus S. Rocha, Gustavo Gössling, Carlos G. Ferreira
Format:	Artigo
Idioma:	Inglês
Publicat:	American Society of Clinical Oncology 2026-06-01
Col·lecció:	JCO Global Oncology
Accés en línia:	https://ascopubs.org/doi/10.1200/GO-26-00042
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!